(Q47429603)

English

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies

scientific article published in February 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies (English)

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

darbepoetin alfa

0 references

David Scott Miller

24

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

author name string

Paul J Hesketh

1

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Francis Arena

2

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Dhimant Patel

3

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Matt Austin

4

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Paul D'Avirro

5

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Gregory Rossi

6

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Alan Colowick

7

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Lee Schwartzberg

8

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Luigi F Bertoli

9

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

John T Cole

10

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

George Demetri

11

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Emmanuel Dessypris

12

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Tracy Dobbs

13

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Peter Eisenberg

14

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Roger Fleischman

15

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

James Hall

16

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Phillip C Hoffman

17

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Damian A Laber

18

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

John Leonard

19

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Eric P Lester

20

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Spence McCachren

21

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Scott McMeekin

22

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Luis Meza

23

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Sucha Nand

25

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Ira Oliff

26

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Warren Paroly

27

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Larry Pawl

28

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Alejandra Perez

29

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Harry Raftopoulos

30

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

James Rigas

31

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Kendrith Rowland

32

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Daniel C Scullin

33

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Haluk Tezcan

34

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

John Waples

35

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

John Ward

36

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Lorrin K Yee

37

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

language of work or name

0 references

publication date

1 February 2004

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

100

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

4

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

859-868

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

21 January 2018

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of therapeutic protein in vivo activities through glycoengineering

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11954

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11954

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

1 reference

Europe PubMed Central

16 January 2018

http://europepmc.org/abstract/MED/14770445

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47429603&oldid=2156463385"